Inder S. Anand
YOU?
Author Swipe
View article: Authorship-contribution normalized Sh-index and citations are better research output indicators
Authorship-contribution normalized Sh-index and citations are better research output indicators Open
Bibliometric measures, such as total citations and h-index, have become a cornerstone for evaluating academic performance; however, these traditional metrics, being non-weighted, inadequately capture the nuances of individual contributions…
View article: Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF
Sacubitril/valsartan and quality of life assessed using the EuroQol Five-dimension Three-level questionnaire level sum score (EQ-5D-3L-LSS) in patients with HFrEF and HFmrEF/HFpEF Open
Aims To investigate the EQ-5D-3L Level Sum Score (LSS) in patients with heart failure (HF) and reduced (HFrEF) and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and the effect of sacubitril/valsartan on this score using pati…
View article: Traditional Medicinal Plants and Their Uses in Diabetes Management
Traditional Medicinal Plants and Their Uses in Diabetes Management Open
Diabetes mellitus, a chronic metabolic disorder characterized by elevated blood glucose levels, poses a significant global health challenge. While conventional pharmaceutical interventions are critical for managing diabetes, traditional me…
View article: Diabetes and its Management from Medicinal Plants: A Comprehensive Review of Phytotherapeutic Approaches
Diabetes and its Management from Medicinal Plants: A Comprehensive Review of Phytotherapeutic Approaches Open
Diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia, poses a significant global health challenge. While conventional pharmacotherapy effectively manages blood glucose levels, limitations such as side effects, cos…
View article: Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial
Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial Open
View article: Comprehensive Introduction to ASIAN-HF Registry
Comprehensive Introduction to ASIAN-HF Registry Open
A Prospective Observational Study Study Period: 2012-09 to 2020-03 Study Data Overview (ASIAN HF Registry, A Prospective Observational Study [ASIANHF]; NCT01633398).
View article: Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF
Effects of Sacubitril/Valsartan According to Natriuretic Peptide Levels in Patients Enrolled in PARADIGM-HF and PARAGON-HF Open
The relative risk reductions with sacubitril/valsartan were consistent irrespective of NT-proBNP level in HF patients across the range of LVEF. Consequently, the absolute risk reductions were greatest in patients with higher NT-proBNP leve…
View article: Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin Open
In DAPA-HF, elevated IL-6 and hs-CRP levels were each associated with the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of adverse outcomes regardless of baseline IL-6 or hs-CRP. (Study to Evaluate the Effect…
View article: Nutrition and Dietary Patterns: A Comprehensive Review of Awareness, Guidelines, and Healthful Practices”
Nutrition and Dietary Patterns: A Comprehensive Review of Awareness, Guidelines, and Healthful Practices” Open
Nutrition forms the foundation of health and wellbeing, influencing both physical and mental performance across all stages of life. In the face of changing dietary patterns, increased consumption of processed foods, and limited nutritional…
View article: Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial
Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Preserved Trial Open
Investigator adjudication is an alternative to a CEC with similar accuracy and faster event accumulation in HFpEF. The use of granular (SCTI) criteria did not improve trial performance. Our data suggest that a broader definition of an HHF …
View article: Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM‐HF and PARAGON‐HF
Clinical Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction and With Reduced Ejection Fraction According to the Prognostic Nutritional Index: Findings From PARADIGM‐HF and PARAGON‐HF Open
Background The importance of nutritional status is underappreciated in patients with heart failure (HF). This study aimed to describe the range of the prognostic nutrition index (PNI), and the clinical characteristics and outcomes accordin…
View article: Systolic Blood Pressure and Pulse Pressure in Heart Failure
Systolic Blood Pressure and Pulse Pressure in Heart Failure Open
View article: Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF
Clinical Correlates and Prognostic Impact of Cognitive Dysfunction in Patients With Heart Failure and Preserved Ejection Fraction: Insights From PARAGON-HF Open
BACKGROUND: Cognitive impairment is common in patients with heart failure and preserved ejection fraction but its clinical correlates and prognostic associations are poorly understood. METHODS: We analyzed cognitive function, using the Min…
View article: Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction
Beta‐blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction Open
Aims In the absence of randomized trial evidence, we performed a large observational analysis of the association between beta‐blocker (BB) use and clinical outcomes in patients with heart failure (HF) and mildly reduced (HFmrEF) and preser…
View article: Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction
Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction Open
The same NT-proBNP concentration predicts a substantially higher absolute risk of adverse outcomes for people with heart failure and reduced kidney function, compared with those with preserved kidney function. These data call into question…
View article: Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment
Clinical characteristics and outcomes of patients aged 80 years and over with heart failure: Need for better treatment Open
Aims Although the prevalence of heart failure (HF) increases markedly with advancing age, surprisingly little is known about HF in the very elderly. The aim of this study was to describe the clinical characteristics and outcomes of octogen…
View article: Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with the ASIAN‐HF registry
Heart failure with improved versus persistently reduced left ventricular ejection fraction: A comparison of the BIOSTAT‐CHF (European) study with the ASIAN‐HF registry Open
Aims We investigated the prevalence, clinical characteristics, and prognosis of patients with heart failure (HF) with improved ejection fraction (HFimpEF). Methods and results We used data from BIOSTAT‐CHF including patients with a left ve…
View article: Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction
Low Natriuretic Peptide Levels and Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Open
View article: Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF
Effect of Sacubitril/Valsartan on Cognitive Function in Patients With Heart Failure With Preserved Ejection Fraction: A Prespecified Analysis of PARAGON-HF Open
BACKGROUND: A hypothetical concern has been raised that sacubitril/valsartan might cause cognitive impairment because neprilysin is one of several enzymes degrading amyloid-β peptides in the brain, some of which are neurotoxic and linked t…
View article: Revisiting Race and the Benefit of RAS Blockade in Heart Failure
Revisiting Race and the Benefit of RAS Blockade in Heart Failure Open
Importance Concerns have arisen that renin-angiotensin system (RAS) blockers are less effective in Black patients than non-Black patients with heart failure and reduced ejection fraction (HFrEF). Objective To determine whether the effects …
View article: Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Cardiovascular-Kidney-Metabolic Overlap in Heart Failure With Mildly Reduced or Preserved Ejection Fraction Open
View article: Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials
Cost Effectiveness of Dapagliflozin for Heart Failure Across the Spectrum of Ejection Fraction: An Economic Evaluation Based on Pooled, Individual Participant Data From the DELIVER and DAPA‐HF Trials Open
Background The sodium glucose cotransporter‐2 inhibitors are guideline‐recommended to treat heart failure across the spectrum of left ventricular ejection fraction; however, economic evaluations of adding sodium glucose cotransporter‐2 inh…
View article: High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT
High-sensitivity C-reactive protein in heart failure with preserved ejection fraction: Findings from TOPCAT Open
View article: Clinical Features of Heart Failure With Normal Ejection Fraction
Clinical Features of Heart Failure With Normal Ejection Fraction Open
View article: Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure
Association of Carbohydrate Antigen 125 on the Response to Dapagliflozin in Patients With Heart Failure Open
In DAPA-HF, elevated CA125 levels were an independent predictor of the risk of worsening HF or cardiovascular death. Dapagliflozin reduced the risk of worsening HF or cardiovascular death regardless of baseline CA125.
View article: Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification?
Clinical Characteristics and Outcomes in Patients With Heart Failure: Are There Thresholds and Inflection Points in Left Ventricular Ejection Fraction and Thresholds Justifying a Clinical Classification? Open
BACKGROUND: Recent guidelines proposed a classification for heart failure (HF) on the basis of left ventricular ejection fraction (LVEF), although it remains unclear whether the divisions chosen were biologically rational. Using patients s…
View article: Stroke in patients with heart failure and reduced or preserved ejection fraction
Stroke in patients with heart failure and reduced or preserved ejection fraction Open
Aims Stroke is an important problem in patients with heart failure (HF), but the intersection between the two conditions is poorly studied across the range of ejection fraction. The prevalence of history of stroke and related outcomes were…
View article: Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation
Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation Open
BACKGROUND: The rate of stroke in patients with heart failure (HF) and preserved ejection fraction but without atrial fibrillation (AF), is uncertain as is whether it is possible to reliably predict the risk of stroke in these patients. ME…
View article: Patient-Reported Status and Heart Failure Outcomes in Asia by Sex, Ethnicity, and Socioeconomic Status
Patient-Reported Status and Heart Failure Outcomes in Asia by Sex, Ethnicity, and Socioeconomic Status Open
View article: Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction
Omecamtiv Mecarbil in Black Patients With Heart Failure and Reduced Ejection Fraction Open
GALACTIC-HF enrolled more Black patients than other recent HF trials. Black patients treated with omecamtiv mecarbil had similar benefit and safety compared with White counterparts.